EUVIMEDEUVIMED entdecken
Crossref

Anti-Acute Myeloid Leukemia Activity of CD38-CAR-T Cells with PI3Kδ Downregulation

Na An, Yuming Pan, Linlin Yang, Qiongli Zhang, Sisi Deng, Qiaoxia Zhang, Xin Du iD

Molecular Pharmaceutics · 01.05.2023 · 20 (5) · 2426-2435

DOI: 10.1021/acs.molpharmaceut.2c00913 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 06.04.2023. Verfasst von Na An und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Institute of Hematology, Shenzhen Second People's Hospital, The First Affiliat…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Shenzhen Key Medical Discipline Construction Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We previously constructed a nanobody-based anti-CD38 chimeric antigen receptor T (CD38-CAR-T) cell efficiently against multiple myeloma. As CD38 is also expressed on most tumor cells of acute myeloid leukemia (AML), we wondered about its efficacy in treating AML. In this study, we demonstrated that our CD38-CAR-T cells effectively lysed CD38+ AML cell lines, including NB4, U937, HL-60, THP-1 with an E:T (effector/target cells) ratio of 1:8, and primary AML cells from patients with a low E:T ratio of 1:16. Moreover, recent studies showed that inhibition of PI3Kδ could enhance CAR-T-cell efficacy. We constructed PI3Kδ-downregulated CD38-CAR-T cells with a CD38-CAR lentiviral vector containing short hairpin RNA (shRNA) sequences against PI3Kδ. CD38-CAR-T cells with PI3Kδ downregulation maintained their antileukemia function against both AML cell lines and primary AML cells while reducing the release of IL-2, IFN-γ, and TNF when co-culturing with AML cell lines. Both CD38-CAR-T and PI3Kδ-downregulated CD38-CAR-T-cell therapy significantly improved the survival of AML mice, whereas the latter had an even better effect on survival. In summary, our study demonstrated that CD38-CAR-T cells had promising activity against AML, and PI3Kδ downregulation in CD38-CAR-T cells could reduce some cytokines release without impairing their antileukemia function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteReceptors, Chimeric AntigenAnimalsMiceCell Line, TumorDown-RegulationImmunotherapy, AdoptiveT-LymphocytesADP-ribosyl Cyclase 1Class I Phosphatidylinositol 3-Kinases

Stichwörter der Autor:innen

CD38PI3Kδacute myeloid leukemiachimeric antigen receptorcytokine release syndrome

Substanzen

Receptors, Chimeric AntigenADP-ribosyl Cyclase 1Class I Phosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Institute of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen University Health Science…

ORCID-Profile: Xin Du

Förderung

  • National Natural Science Foundation of China
  • Guangdong Basic and Applied Basic Research Foundation
  • Shenzhen Key Medical Discipline Construction Fund

Zitieren

APA

An, N., Pan, Y., Yang, L., Zhang, Q., Deng, S., Zhang, Q., & Du, X. (2023). Anti-Acute Myeloid Leukemia Activity of CD38-CAR-T Cells with PI3Kδ Downregulation. Molecular Pharmaceutics, 20(5), 2426-2435. https://doi.org/10.1021/acs.molpharmaceut.2c00913

Vancouver

An N, Pan Y, Yang L, Zhang Q, Deng S, Zhang Q, et al. Anti-Acute Myeloid Leukemia Activity of CD38-CAR-T Cells with PI3Kδ Downregulation. Molecular Pharmaceutics. 2023;20(5):2426-2435. doi:10.1021/acs.molpharmaceut.2c00913

BibTeX
@article{An2023,
  author = {An, Na and Pan, Yuming and Yang, Linlin and Zhang, Qiongli and Deng, Sisi and Zhang, Qiaoxia and Du, Xin},
  title = {Anti-Acute Myeloid Leukemia Activity of CD38-CAR-T Cells with PI3Kδ Downregulation},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  volume = {20},
  number = {5},
  pages = {2426--2435},
  doi = {10.1021/acs.molpharmaceut.2c00913}
}
Kostenlos starten →